485MO Health-related quality of life (HRQoL) from the PATINA trial (AFT-38): Impact of adding palbociclib to HER2 and endocrine therapy (ET) after induction in HR+/HER2+ metastatic breast cancer (MBC)

Inês Vaz-Luís, Graziella Mazza, J. Gligorov, Eunji Lim, E. Ciruelos, S. Loibl, Angela DeMichele, Briant Fruth, Xavier González, Prudence A. Francis, F. Lynce, Jessie Chien, Suzette Delaloge, Kathy D. Miller, EP Winer, Sumithra J. Mandrekar, Shom Goel, L. Carey, A.H. Partridge, Otto Metzger